A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Trial ID # NCT01891344; ARIEL2
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Rucaparib
Alternate Drug Names AG-014699, PF 01367338, CO-338, Rubraca
Drugs in Trial Rucaparib
Eligible Participant

Platinum sensitive ovarian cancer at first recurrence (ARIEL2, Part 1)

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, PFS, evaluated per RECIST


Exploratory: BRCA1/2; LOH (by FoundationFocus CDx BRCA LOH)


Data from ARIEL2, Part 1:
BRCA MUT (n=40) vs BRCA WT LOH high (n=82) vs BRCA WT LOH low (n=70):

ORR: 80 vs 29 vs 10%
PFS: 12.8 vs 5.7 vs 5.2 months, HR: 0.27 (0.16-0.44, p<0.0001); HR: 0.62 (0.42-0.90, p=0.011)

Clinically Significant Adverse Events

Serious AE: none
Grade 3-4 AE: anemia or decreased hemoglobin (22%), elevated liver enzymes (13%)


Improved ORR and PFS with rucaparib treatment in BRCA MUT patients


Swisher EM et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol (2017) 18(1):75-87

Swisher EM et al. Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC). J Clin Oncol (2020) 38: (suppl; abstr 6015)

Swisher EM et al. Poster

Swisher EM et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun (2021) 12(1):2487

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.